Topic: Manufacturing Facilities
WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.
A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.
Esteve has a deal to buy a specialty drug manufacturing plant in Germany after selling a its generics business and plant in Spain.
UCB, which recently paid $2.5 billion for an autoimmune drug candidate, will build a $333 million facility and staff it with 150 workers.
Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.
The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.
FDA gives Biocon Biologics nod to producing Fulphila at plant in India.
Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.
With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.
A Novartis ingredient operation in China is being hived off as the Swiss drugmaker continues its drive to cut manufacturing jobs.